Bioanalysis Built for Confident Development
Integrated GLP/GCP bioanalytical support for small molecules, biologics, nucleic acids, biomarkers, and advanced pharmacokinetic programs.
End-to-end analytical programs for discovery through clinical phases
Choose a service area below to open the detailed local page for that capability.
Small Molecule Bioanalysis
Validated LC-MS/MS workflows for generics and novel small molecule programs.
Explore capability ->Animal Health
Bioanalytical support for veterinary medicines and companion animal studies.
Explore capability ->Bioequivalence Studies
Study-ready analytical support for generic product submissions and comparative PK.
Explore capability ->Biologics & Biosimilars
Immunogenicity, ligand-binding assays, and complex biologics bioanalysis.
Explore capability ->Nucleic Acids
Specialized workflows for oligonucleotides, RNA, and related therapeutic modalities.
Explore capability ->Biomarker Analysis
Translational biomarker strategy, assay development, and regulated sample testing.
Explore capability ->PK Evaluation & Statistics
Pharmacokinetic evaluation and statistical support for study interpretation.
Explore capability ->Percutaneous Absorption
In vitro absorption and topical/transdermal performance support.
Explore capability ->Enzyme Activity
Functional assay programs for potency, activity, and mechanism-focused endpoints.
Explore capability ->
Designed around regulated studies and practical timelines
Our teams combine analytical method development, matrix-specific validation, high-throughput sample analysis, and clear reporting so development teams can move with confidence.
- GLP/GCP aligned study execution for clinical and preclinical sample analysis.
- Flexible assay platforms across LC-MS/MS, ligand-binding assays, qPCR, and cell-based endpoints.
- Integrated reporting for regulatory packages, bioequivalence reviews, and sponsor decision-making.